Idorsia Pharmaceuticals Ltd.
IDIADrugs in Pipeline
20
Phase 3 Programs
10
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Daridorexant 10 mg
Insomnia Disorder
Daridorexant
Insomnia Disorder
Cetirizine
Seasonal Allergic Rhinitis
Aprocitentan 12.5 mg
Resistant Hypertension
Lucerastat
Fabry Disease
Clazosentan
Aneurysmal Subarachnoid Hemorrhage
tezosentan
Acute Heart Failure
Daridorexant 50 mg
Insomnia Disorder
Daridorexant 25 mg
Insomnia
ACT-129968
Seasonal Allergic Rhinitis
ACT-539313
Binge-Eating Disorder
ACT-541468 5 mg
Insomnia Disorder
ACT-709478 for oral use
Photosensitive Epilepsy
Aprocitentan 5 mg
Essential Hypertension
Clazosentan 1 mg/h
Aneurysmal Subarachnoid Hemorrhage
ACT-541468
Insomnia Disorder
ACT-774312
Bilateral Nasal Polyposis
ACT-280778
Essential Hypertension
Setipiprant
Asthma
Zolpidem
Insomnia Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Daridorexant 10 mg | Phase 3 | Insomnia Disorder | - | - |
Daridorexant | Phase 3 | Insomnia Disorder | - | - |
Cetirizine | Phase 3 | Seasonal Allergic Rhinitis | - | - |
Aprocitentan 12.5 mg | Phase 3 | Resistant Hypertension | - | - |
Lucerastat | Phase 3 | Fabry Disease | - | - |
Clazosentan | Phase 3 | Aneurysmal Subarachnoid Hemorrhage | - | - |
tezosentan | Phase 3 | Acute Heart Failure | - | - |
Daridorexant 50 mg | Phase 3 | Insomnia Disorder | - | - |
Daridorexant 25 mg | Phase 3 | Insomnia | - | - |
ACT-129968 | Phase 3 | Seasonal Allergic Rhinitis | - | - |
ACT-539313 | Phase 2 | Binge-Eating Disorder | - | - |
ACT-541468 5 mg | Phase 2 | Insomnia Disorder | - | - |
ACT-709478 for oral use | Phase 2 | Photosensitive Epilepsy | - | - |
Aprocitentan 5 mg | Phase 2 | Essential Hypertension | - | - |
Clazosentan 1 mg/h | Phase 2 | Aneurysmal Subarachnoid Hemorrhage | - | - |
ACT-541468 | Phase 2 | Insomnia Disorder | - | - |
ACT-774312 | Phase 2 | Bilateral Nasal Polyposis | - | - |
ACT-280778 | Phase 2 | Essential Hypertension | - | - |
Setipiprant | Phase 2 | Asthma | - | - |
Zolpidem | Phase 2 | Insomnia Disorder | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Idorsia Pharmaceuticals Ltd.'s drug pipeline?→
CatalystAlert tracks 20 drug candidates in Idorsia Pharmaceuticals Ltd.'s (IDIA) pipeline across Phase 3, Phase 2. Its lead program is Daridorexant 10 mg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Idorsia Pharmaceuticals Ltd.'s next FDA catalyst?→
Idorsia Pharmaceuticals Ltd.'s (IDIA) next tracked catalyst is a PDUFA expected December 27, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IDIA biotech catalysts?→
Add IDIA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Idorsia Pharmaceuticals Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.